News
UROV
16.24
0.00%
0.00
Webull provides a variety of real-time UROV stock news. You can receive the latest news about Urovant Sciences through multiple platforms. This information may help you make smarter investment decisions.
About UROV
Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for urologic conditions. Its product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist. is focused on evaluating vibegron in its over 1,400 patients, pivotal phase-3 clinical trial for the treatment of overactive bladder (OAB). The Company’s subsidiaries include Urovant Sciences, Inc., Urovant Holdings Limited, and Urovant Sciences GmbH.